Medical Products & Consumables Procurement Optimisation · Data Sheet
Medical Products & Consumables Procurement — Financial Results
Opportunity modelling, validation status and portfolio economics — with every figure classified by how far it has actually been proven.
Result status
Modelled and provisional procurement opportunity. Not represented as fully realised savings. Commercial benefit is recognised only once data, product suitability, supplier terms and implementation evidence support it.
Baseline portfolio architecture
Twelve months of supplier invoices, segmented
Scroll table sideways →
| Sector | Annual spend | Portfolio share | Initial modelled opportunity | Sector rate |
|---|---|---|---|---|
| Primary ostomy products | R8,895,870.32 | 73.71% | R158,452.92 | 1.78% |
| Ostomy ancillary / support products | R2,478,020.83 | 20.53% | R780,324.88 | 31.49% |
| General medical consumables | R695,295.79 | 5.76% | R53,768.38 | 7.73% |
| Total | R12,069,186.95 | 100.00% | R992,546.18 | 8.22% |
Opportunity development
How the position moved, and what it was worth at each stage
Scroll table sideways →
| Stage | Recorded position | Status |
|---|---|---|
| Reconstructed baseline | R12.069m annual portfolio across three sectors | Spend architecture establishing the review universe |
| Initial optimisation model | R992,546.18 per annum / 8.22% of baseline | Modelled opportunity — product and data validation still required |
| Supplier-engagement model | R1,788,234.30 per annum | Later provisional position after incumbent engagement and additional price work; checks and acceptance still underway |
| Clinical-acceptance exposure | R603,754.59 primary + R105,669.28 ancillary | ≈39.7% of the later provisional model depended on whether specific alternatives were accepted |
| Realised result | Not established as a single final figure | No publication claim is made for full realised savings without implementation and purchasing evidence |
Supplier concentration
Leverage and dependency are the same fact
Scroll table sideways →
| Sector | Leading supplier share | Procurement implication |
|---|---|---|
| Primary ostomy products | 73.4% | Material negotiating leverage, but patient continuity and product dependency limit simple switching |
| Ostomy ancillary / support | 74.7% | High concentration creates meaningful repricing opportunity, subject to interchangeability |
| General medical consumables | 88.1% | Strong concentration suggests market-testing potential and heightened supply-dependency risk |
Where the opportunity sat
Why portfolio size is the wrong guide
Scroll table sideways →
| Measure | Primary | Ancillary | Consumables |
|---|---|---|---|
| Portfolio share | 73.71% | 20.53% | 5.76% |
| Initial opportunity rate | 1.78% | 31.49% | 7.73% |
| Share of total initial opportunity | 15.96% | 78.62% | 5.42% |
Primary products were almost three-quarters of spend and produced under a sixth of the opportunity. Ancillary products were a fifth of spend and produced nearly four-fifths of it. Substitution flexibility and price dispersion drive the result, not category size.
Data quality
Reconciliation notes carried from the source
- Reconciled baseline. The sector table totals R12,069,186.95. One narrative line in the early presentation states R12,068,735.75 — a R451.20 difference. The sector-reconciled total is used.
- Changing price base. Later workbooks incorporated supplier repricing and price movements, so later opportunity figures must not be divided mechanically by the original baseline without confirming the spend base is the same.
- Anomaly review. Invoice anomalies of R42,478.36 were identified across three supplier groups, roughly 80.6% concentrated in one. A variance is a question until the supplier confirms or disputes it, and a supplier counter-position may follow — reconciliation and documentary support are required before an anomaly becomes a recovery.
- Clinical gate. Where a cheaper product was not accepted, the associated opportunity had to be reduced or removed rather than carried as a saving.
Result interpretation
The strongest financial result here is not a single headline number. It is the separation of a R12m-plus procurement portfolio into evidence-backed spend, commercially modelled opportunity, clinically contingent opportunity, and ultimately implementable value.
Neither R992,546.18 nor R1,788,234.30 is presented as a fully realised annual saving.